Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in USD (TTM)27.54bn
- Net income in USD1.18bn
- Incorporated1925
- Employees49.10k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICON PLC | 8.12bn | 612.34m | 27.71bn | 41.10k | 45.39 | 3.00 | 23.12 | 3.41 | 7.40 | 7.40 | 98.17 | 112.02 | 0.4752 | -- | 2.99 | 197,571.20 | 3.59 | 3.93 | 4.28 | 4.80 | 29.66 | 28.91 | 7.55 | 7.37 | -- | 3.15 | 0.2901 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Biogen Inc | 9.84bn | 1.16bn | 31.34bn | 7.57k | 27.03 | 2.11 | 18.92 | 3.19 | 7.98 | 7.98 | 67.67 | 102.14 | 0.3827 | 1.31 | 4.64 | 1,299,287.00 | 4.52 | 12.53 | 5.20 | 14.83 | 74.24 | 81.84 | 11.81 | 26.93 | 1.26 | 3.86 | 0.3192 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
DuPont de Nemours Inc | 12.07bn | 494.00m | 32.02bn | 24.00k | 73.93 | 1.36 | 19.06 | 2.65 | 1.04 | 0.9256 | 26.77 | 56.45 | 0.302 | 3.50 | 4.94 | 502,833.30 | 1.33 | 0.3709 | 1.48 | 0.468 | 35.08 | 35.69 | 4.42 | 1.97 | 1.73 | 6.61 | 0.2398 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
Gartner Inc | 5.91bn | 882.47m | 37.16bn | 20.24k | 43.08 | 54.86 | 34.62 | 6.29 | 11.07 | 11.07 | 74.13 | 8.69 | 0.7805 | -- | 3.68 | 291,888.90 | 11.66 | 8.24 | 22.74 | 14.76 | 67.78 | 67.55 | 14.94 | 12.20 | -- | 12.01 | 0.7832 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
Moderna Inc | 6.85bn | -4.71bn | 40.80bn | 5.60k | -- | 2.94 | -- | 5.96 | -12.39 | -12.39 | 17.68 | 36.27 | 0.3093 | 8.15 | 6.01 | 1,222,857.00 | -21.29 | 20.95 | -25.94 | 29.51 | 31.47 | -- | -68.84 | 32.10 | 3.36 | -- | 0.0399 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
Takeda Pharmaceutical Co Ltd (ADR) | 27.54bn | 1.18bn | 43.95bn | 49.10k | 37.28 | 0.9786 | 7.55 | 1.60 | 0.3726 | 0.3726 | 8.74 | 14.19 | 0.3007 | 1.29 | 5.86 | 560,996.20 | 1.29 | 1.79 | 1.54 | 2.14 | 67.52 | 68.57 | 4.28 | 6.81 | 0.5518 | 2.83 | 0.4089 | 121.86 | 12.85 | 17.87 | 37.80 | 11.15 | 37.64 | -- |
Iqvia Holdings Inc | 14.98bn | 1.36bn | 45.90bn | 87.00k | 34.65 | 7.51 | 18.49 | 3.06 | 7.30 | 7.30 | 80.42 | 33.67 | 0.5761 | -- | 4.76 | 172,229.90 | 5.22 | 3.24 | 6.80 | 4.07 | 34.96 | 34.32 | 9.06 | 6.03 | -- | 3.24 | 0.6911 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
Data as of Mar 28 2024. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: US Dollar USD
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 14.30m | 0.45% |
Mondrian Investment Partners Ltd.as of 31 Dec 2023 | 8.17m | 0.26% |
Millennium Management LLCas of 31 Dec 2023 | 6.49m | 0.21% |
Parametric Portfolio Associates LLCas of 31 Dec 2023 | 3.88m | 0.12% |
Renaissance Technologies LLCas of 31 Dec 2023 | 3.33m | 0.11% |
Brandes Investment Partners LPas of 31 Dec 2023 | 2.65m | 0.08% |
Macquarie Investment Management Business Trustas of 31 Dec 2023 | 2.45m | 0.08% |
Strategic Advisers LLCas of 31 Dec 2023 | 2.11m | 0.07% |
Arrowstreet Capital LPas of 31 Dec 2023 | 1.91m | 0.06% |
TFG Asset Management UK LLPas of 31 Dec 2023 | 1.90m | 0.06% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.